Clinical Trial

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 3, 2021 (before its estimated February 2, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center,randomized,phase 3 clinical trial. In the study, HER2-positive metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway after progression on trastuzumab are enrolled and randomized to receive the treatment of Inetetamab plus Rapamycin plus chemotherapy or Pyrotinib plus chemotherapy.The study aimed to access the efficacy and safety of Inetetamab combined with Rapamycin and chemotherapy in HER2-positive metastatic breast cancer patients with abnormal activation of PI3K/Akt/mTOR pathway.
Trial Details
NCT Number NCT04736589
Lead Sponsor Peking Union Medical College
Conditions Breast Cancer
Enrollment 270 participants
Start Date 2021-02-02
Primary Completion 2024-02-02 (estimated)
Study Completion 2027-02-02 (estimated)
Updated on ClinicalTrials.gov 2021-02-03